Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage neuroscience company f...
Prothena Corporation plc (Nasdaq: PRTA) is a cl...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
InMode Ltd. (Nasdaq: INMD) is a leading global provider of innovative medical tech...
InMode Ltd. (Nasdaq: INMD) is a leading global ...
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials compa...
PolarityTE is a commercial-stage biotechnology ...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...
Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...
ImmuCell Corporationâs (Nasdaq: ICCC) purpose is to create scientifically-proven...
ImmuCell Corporationâs (Nasdaq: ICCC) purpose...
IVERIC bio is a gene therapy focused company developing innovative treatments for ...
IVERIC bio is a gene therapy focused company de...
Join the National Investor Network and get the latest information with your interests in mind.